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Abstract 
Background: Cancer is a heterogeneous disease, which is based on an intricate network of processes at different spatiotemporal scales, from the genome 
to the tissue level. Hence the necessity for the biomedical and pharmaceutical research to work in a multiscale fashion. In this respect, a significant help 
derives from the collaboration with theoretical sciences. Indeed, mathematical models can provide insights into tumor-related processes and support 
clinical oncologists in the design of treatment regime, dosage, schedule and toxicity. Objective and Method: The main objective of this article is to review 
the recent computational-based patents which tackle some relevant aspects of tumor treatment. We first analyze a series of patents which concern the 
purposing or repurposing of anti-tumor compounds. These approaches rely on pharmacokinetics and pharmacodynamics modules, that incorporate data 
obtained in the different phases of clinical trials. Similar methods are also at the basis of other patents included in this paper, which deal with treatment 
optimization, in terms of maximizing therapy efficacy while minimizing side effects on the host. A group of patents predicting drug response and tumor 
evolution by the use of kinetics graphs are commented as well. We finally focus on patents that implement informatics tools to map and screen biological, 
medical, and pharmaceutical knowledge. Results and Conclusions: Despite promising aspects (and an increasing amount of the relative literature), we 
found few computational-based patents: there is still a significant effort to do for allowing modelling approaches to become an integral component of the 
pharmaceutical research. 
 
Key words: cancer treatment, database screening, drug purposing, drug repurposing, mathematical models, pharmacokinetics/pharmacodynamics models, 
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1. INTRODUCTION  
Cancer is still one of the leading causes of death in the world, and major efforts have been undertaken to improve diagnosis and therapy [1,2]. However, 
recent technical improvements in high-throughput data generation and scientific advances, accompanied by ever increasing investments, have not yet 
provided the awaited success [3–5].  This is chiefly because cancer is a complex and heterogeneous disease [6], involving an intricate network of 
mechanisms that span different spatiotemporal scales that include microscopic, mesoscopic, and macroscopic levels. In particular, the microscopic scale 
refers to processes that occur at the subcellular level, such as DNA synthesis, duplication and gene mutations. The mesoscopic scale refers to single cell-
level phenomena, such as pathological adhesive interactions between cancer cells or between them and ECM components, uncontrolled cell duplication 
and death, as well as altered cell migration and metastasis. Finally, the macroscopic scale corresponds to multicellular collective dynamics, such as tissue 
invasion by malignant masses.  
 Such a multitude of intricate and interacting processes represents a challenge for biomedicine and pharmaceutical companies, that could be helped by the 
collaboration with mathematical and computational sciences. Indeed, in silico simulations, that reproduce the actual biological events, are able to 
accurately predict measurable features, to reduce the experimental burden and to enable rapid, economical and targeted analyses. Further, mathematical 
tools, based on testable hypotheses, are inherently quantitative, integrate potentially high dimensional data from multiple sources and allow a mechanistic 
analysis of the system (be it a pathway snapshot, a cell, an organ or, albeit with limited scope, a virtual human framework). Finally, mathematical models 
are particularly useful when experimental solutions are either impossible, too complicated to perform, or too expensive. In silico approaches can 
complement or replace experiments when they are dangerous or unethical as well. Multilevel mathematical models can also concur to the optimization of 
clinical protocols and provide a useful guide for possible future experiments. 
 
The development of a successful cancer model is however a long-term process and requires a standardized and iterative workflow (Fig.1), typical of a 
multidisciplinary systems biology approach. In more details, the derivation of a powerful mathematical tool first involves the description of experimental 
observations (conceptual phase) and then their translation into formal analytical representations (formalization phase). A good approach is to build the 
simplest model, focused on a single scale/level of abstraction and based on a minimal set of assumptions, with a workable number of independent variables 
and parameters. As a matter of fact, models characterized by a large enough number of degrees of freedom (free parameters) can in fact be made to fit any 
data, rendering the entire process more like a curve-fitting exercise [5]. This drawback can be avoided by restricting the complexity of the theoretical 
method, at least in the initial stages of its development, as simplicity does not necessarily limit performance. After checking its validity and its robustness 
(in terms of missing data estimation, error and bias reduction) with experimental results (validation phase), it is then possible to gradually add more 
components and more levels of abstraction (development phase).  Available experimental data can be used not only to guide model design but also to 
verify and validate computational outcomes. When the established mathematical tool reaches the desired level of details, as well as it is able to 
qualitatively and/or quantitatively reproduce experimental data, it can be used to predict the results of new experiments (predictive phase). Obviously, such 
predictions have to be challenged and assessed by further experimental analysis: indeed, the computational model should be continuously tested by 
performing systematic experimental validation. This continuous feedback and feedforward between in silico and experimental techniques helps to refine 
previous knowledge or to generate new hypotheses. 
 
The results of the above-described multidisciplinary workflow depend on the experimental data used in the different steps. In principle, the growing 
quantities of biological and biomedical outcomes obtained from Omics technologies (high-throughput technologies for characterizing genome, epigenome, 
transcriptome, proteome, metabolome, and interactome) and from clinical trials are not necessarily matched by an increment in the quality of the resulting 
information, being data potentially subjected to noise, various design and selection biases [5,7,8]. A preliminary step in a model development should be a 
quality control over the data used to set up the mathematical approach. For instance, some bioinformatics techniques have been recently established to 
prevent data overfitting and to deal with filtering and error elimination [9,10]. 
 
Despite such issues, systems biology approaches are producing a great amount of knowledge in the context of translational (from bench to bedside) and 
clinical oncology. In particular, in the last couple of decades, mathematical models have provided novel insights into: 
i) descriptive and predictive aspects of tumor growth, progression, angiogenesis and relative immune response [11–24]; 
ii) target identification and drug discover, with particular emphasis on the prediction of drug effects in humans for speeding up clinical trials [25–27]; 
iii) development and efficacy of oncological treatment protocols, focusing on the design of treatment regime (including surgery, radiation and 
chemotherapy and their possible combination) as well as of dosage, schedule, toxicity, sensitivity and resistance to drugs [28–31]. 
 
It is useful to notice that the US FDA Critical Path initiative identified in silico modeling (application of mathematics, statistics and computational 
analysis) as a key challenging area in the development of new or improved drugs [32,33]. 
 
The increasing interest in biomathematics and the huge related literature are however accompanied so far by a very limited number of theoretical-based 
patents, which will be discussed in the next section (see also Table 1 for the most relevant).   
Table 1. List Of The Most Relevant Patents Reviewed In This Work, Their Focus And Mathematical Ingredients.  
 
Patent reference Author(s) Addressed problem Mathematical ingredients 
[34,35] 
Zoref et al. 
Arakelyan et al. 
optimization of drug development PK/PD models 
[36] Agur et al. optimization of chemotherapy schedule 
PK/PD models 
ODEs for cell proliferation/death 
dynamics 
[37] Vainas et al. 
optimization of docetaxel and G-CSF regimens 
in metastatic breast cancer (MBC) patients 
PK/PD models 
granulopoiesis model 
[38] Kuhn et al. optimization of anti-cancer drug combination kinetic models 
[39] Hopkins et al. optimization of pharmaceutical investigation map of knowledge 
 
 
2. MATHEMATICAL-BASED PATENTS  
Drug development is a lengthy and expensive process. In particular, most of the costs and time needed to develop successful anti-tumor drugs are spent in 
clinical trials whose failure rate exceeds 80% [40]. The conventional method for clinical trials design actually suffers some relevant drawbacks. On the one 
hand, a “trial and error” approach alone can not guarantee that the selected schedules are better than other treatment regimens yet to be tried. Furthermore, 
the number of compounds which can be empirically tested is negligible compared to the potential spectrum of powerful ones. Finally, the “trial and error” 
method does not allow drug repurposing, the determination of a novel use for an existing drug or the rescuing of a failed compound. 
Agur and coworkers have proposed a series of patents dealing with a computational-based interactive technique for purposing a new compound and for 
repurposing a drug, with the aim of optimizing drug development from the pre-clinical phases through Phase-IV [41,34,35]. In particular, purposing of a 
drug involves specific clinical indications and/or patient populations along with a treatment schedule. The repurposing of a compound instead involves a 
change either in the current application of an approved drug or in the intended/tested application of a drug under development. The disclosed techniques 
are based on more than two decades of biomathematical research in the area of disease control optimization and drug modeling: they are finalized to 
simulate the dynamics of key biological, pathological and pharmacological processes in a patient undergoing drug treatment [42–51]. The first stage of the 
mathematical-based approach consists of creating a model of drug pharmacokinetics (PK) and pharmacodynamics (PD). In particular, the PD module is 
designed starting from putative mechanisms of drug activity retrieved from in vivo and in vitro studies. The parameters of drug effect on the different target 
tissues and tumors are empirically estimated and introduced into the model, which already gives a first estimate of the efficacy of the treatment, thereby 
interactively guiding the empirical research to reveal further data. Then, animal studies can be used for setting up the PK module and to adjust the PD 
component. Data on different tumor types, on the effects of multiple doses and of combinations with other drugs can be implemented as well. A toxicity 
module is also designed to account for side effects observed during the animal studies. At this stage, the model has already the capacity to make some 
approximate predictions on drug administration to humans. In particular, known inter-species differences in tissue features are taken into account when 
simulating the PD/PK model in human domains, in order to consider feasible dose ranges. In particular, the authors claim that such procedure offers an 
improvement of the traditional LD10/10 initial dose for Phase-I trials, which is often too low to exert any effect on the disease. Further, at this point, the 
model can be used to predict drug failure due to too toxic doses. Obviously, during the dose-effect testing, the computer model is continuously validated 
and fine-tuned by the observed results. By the end of Phase-I, a fully verified in vivo human model is indeed available, integrating all the existing data in 
the PK/PD of the drug: it can also yield reasonable short-term predictions concerning the effects of definite drug administration schedules on disease 
progression. This involves an exhaustive search in the protocol space (within all the possible treatment schedules) with the aim of searching the therapeutic 
strategies expected to provide the highest response and the lowest toxicity (or a combination of both or any other desired criteria defined by the user) for 
the cancer type of interest. At the onset of Phase-II trials, the treatment schedules proposed by the mathematical approach can be applied in short pilot 
trials, which involve a relatively small number of patients. After the first results are obtained (about 6 months on average), the model has to be adjusted by 
implementing the new data. Finally, a set of intensive computational realizations is carried out to simulate the disease progression during an extended 
period of up to two years: their goal is to predict which of the schedules tested in short-term trials are expected to yield the best results in the long-run. At 
this stage, the effect of each selected schedule is compared with the outcome of the existing therapies for the same indications: in the absence of benefits, a 
“NoGo decision” is recommended. The remaining treatments are instead further tested in Phase-III. Compared with the “trial and error” design, the 
implementation of the proposed mathematical-based interactive clinical approach is expected to save both time and number of patients engaged. Additional 
advantages derive from the use of Bayesian statistics, that integrate all the available biological, medical, pharmacological, and clinical information in a 
predictive perspective [42].  
As gene therapy still faces significant hurdles, cancer therapy greatly depends on chemotherapeutic methods, that suffer of poor selectivity and severe side-
effects. Special drugs are indeed designed to alleviate some of the related symptoms. The already cited Agur’s group has developed a patent [52] aimed to 
optimize chemotherapy schedule by a protocol that minimizes the cytotoxic effects on normal cells in the case of specified conditions and limitations. The 
technique is based on a mathematical model and the relative computer-based software. In particular, two generic types of cells are considered: the host 
cells and the target (tumor) cells. Both populations are further subdivided into cycling and resting (quiescent) cells. Each cell can switch phenotype 
according to its chronological age. Indeed, proper ordinary differential equations (ODEs) allow to calculate the number of cells in each subcompartment at 
every time interval starting from an initial distribution. A probability vector accounts for the variability of cycle lengths while retaining a deterministic 
approach. Tumor heterogeneity is included by differentiating malignant individuals into subpopulations, each of them characterized by distinct parameters 
for their state (e.g., oxygenation). In order to simulate cancer treatment, a pharmacologic component is added to the model: in particular, cell-cycle 
selective and non-selective drugs are taken into account. The distribution of drugs within and around the tumor are modeled by 
pharmacokinetics/pharmacodynamics approaches, which reproduce drug administration protocols. The effects of chemotherapy on cells are modeled as it 
follows: cell-cycle unspecific drugs affect all cell types (normal, malignant, quiescent, proliferating) by blocking their cycle at different stages and causing 
their death (with different delays). On the other hand, cell-cycle specific drugs kill only proliferating cells, both normal and altered. Additional types of 
drugs or events relevant for drug kinetics and dynamics (e.g., rate of absorption, development of tumor resistance, etc.) can be introduced into the model. 
In most cases of anticancer chemotherapy, the dose-limiting toxicity relates to bone marrow suppression: indeed granulopoiesis and thrombopoiesis can be 
chosen as an example of host cells, in order to predict the negative effect of the treatment on them. Model parameters can be estimated from experimental 
studies performed in patient populations. However, due to the huge degree of heterogeneity between malignant tumors, even among similar types, and 
between patients, it would be advantageous to adjust the treatment protocol to the individual case, employing patient-specific data such as age, weight, 
gender, previous reaction to treatment, molecular and genetic markers. The computerized method is indeed set up to check any given treatment and to 
choose a very good one according to user's criteria. The goal is achieved through an operation research tool, the fitness function, which defines how the 
different protocols score to predefined objectives, including the minimal total amount of drug needed for tumor treatment, the shortest period of disease, 
the smallest toxicity, the minimal the damage to the BM cells. 
A further side effect of chemotherapy (and of radiotherapy as well) is neutropenia, that enhances the susceptibility to microbial infections. In particular, 
neutropenia is the dose-limiting toxicity of the tri-weekly docetaxel (Taxotere®) schedule. A common neutropenia alleviating therapy is based on the use 
of Granulocyte Colony Stimulating Factor (G-CSF), mainly administered one day post-docetaxel, for 5-6 consecutive days [53,54]. In this context, Agur 
and colleagues patented a computational method for predicting docetaxel-induced neutropenia, and used the model to identify improved docetaxel and G-
CSF regimens in metastatic breast cancer (MBC) patients [37], see also [55,56]. Their computerized framework integrates and interfaces 
pharmacokinetics/pharmacodynamics (PK/PD) approaches with a mathematical granulopoiesis model. In more details, a three-compartment PK/PD 
module [57,58] is designed to calculate the concentration profile of each compound, with the central and the two peripheral compartments respectively 
representing blood vessels and all body tissues that have direct and fast exchange with blood, such as the BM. In particular, equal or proportional 
compartmental concentrations can be assumed, whereas drug distribution is described as a linear exchange between the connected domains. Following the 
related literature (see, for instance, [59–63] and references therein), the granulopoiesis model reproduces the complex dynamics of mitotic and non-mitotic 
progenitors and of blood neutrophils, with explicit terms of cell-cycle phases. G-CSF is finally modeled as a feedback molecule governing BM 
maintenance of steady neutrophils level in blood, accounting for its secretion, diffusion, clearance and interaction with different cell compartments. The 
cell-cycle structures incorporate experimental data on cell-cycle phase distribution in different BM compartments as well as results from radioactive 
labelling experiments. The granulopoiesis model parameters are instead estimated by a curve-fitting process based on a variety of in vivo experiments, as 
specified in [43]. The model prediction accuracy was originally tested by dividing a set of patients (mainly Caucasian females) into a “training set”, whose 
clinical outcomes were used to adjust model parameters, and a “validation set”, whose medical data were compared to the model-predicted neutrophil 
profiles upon simulation of docetaxel treatment [64]. Summing up, the input data needed to the computational tool comprise only the patient baseline 
neutrophil count and the ascribed docetaxel/G-CSF schedule, whereas the output of the software is the effect of the therapy of interest.  
Multi-drug chemotherapy has been shown to be a more effective treatment than single drug-based ones: indeed, research efforts have endeavored to 
develop methods and models for selecting optimal drug combinations, doses, and schedules. Patent [65] describes a computational approach for tailoring 
optimal cancer multi-drug therapy regimens to individual patients. It can be considered a kinetically tailored treatment (“KITT”) model, which predicts 
therapeutic schedules with the potential to reduce tumor size and prolonging the patient's life, while minimizing side-effects. The disclosed technique is 
also expected to reduce the number of clinical trials to be performed and to produce robust predictions before in vivo studies. The invention includes at 
least three types of anti-cancer drugs: cell-cycle phase-specific (CS), cell-cycle non-specific (nCS), and cytostatic (DR). Pharmacokinetics and 
pharmacodynamics models can be then set up for each compound of interest employing empirical measurements taken directly from patients. In particular, 
the drug concentration is calculated according to the procedure described in [66]. Tumor cells are grouped into two compartments, proliferating and 
quiescent. Proliferating cells may divide, enter the quiescent state, or die from apoptosis, while quiescent cells may die from necrosis or shift to the 
proliferating state. In addition, nCS drugs kill cells both in the resting and in the proliferating states, whereas CS drugs kill only a fraction of proliferating 
cells in a particular phase of their cell cycle. Finally, DR drugs slow cell progression. Tumor individuals are further classified according to their genetic 
make-up, which determines their resistance level to each type of drug. Resistance is assumed to gradually evolve following a probabilistic law. However, 
random mutations may increase the level of cell resistance to a given compound. From a computational viewpoint, chemotherapy is set to begin when a 
tumor reaches a size of 109 cells. Cure success is a stochastic event that depends on the minimum tumor size (the nadir) achieved during treatment. In 
particular, the probability of cure is given by the zeroth term of the Poisson distribution, i.e., Pr(cure)=exp(−nadir). This probability declines very quickly 
as the nadir increases above one cell, and is less than 10−4 for a nadir of only 10 cells. The model measures toxicity in terms of dose intensity, plasma drug 
concentrations, and nadir of the bone marrow stem cell number. The hematopoietic cell population is assumed to have the same kinetics as the tumor cell 
populations although with different parameters. Surgical tumor resection is instead simulated as the removal of the oldest 99% of tumor cells, leaving 1% 
survival of the most recently produced individuals, which are then exposed to adjuvant chemotherapy. The youngest cells are assumed to survive both 
because they can likely metastasize before the extraction of the older bulk of the tumor and because they arise after many generations of clonal evolution, 
thereby being more resistant than their progenitors. Finally, the model predicts uncured tumor growth until a lethal size of 1012 cells. Then, a computer 
program product solves the overall mathematical model, needing only patient-specific proliferative/apoptotic rates, cell cycle parameters and levels of drug 
resistance as required inputs, all of which are data routinely requested by clinical oncologists. The KITT framework is able to analyze a plurality of 
treatment regimens, each having a quantitative efficacy value associated therewith, as the probability of survival, or survival duration, and the minimization 
of side effects. Further, the proposed technique can aid in predicting how rapidly resistance to a particular drug may evolve and in studying potential 
ramifications of treatment modification in a given patient. However, the patent is not free of some shortcomings. First, a spatial component is not present in 
the KITT model embodiment, therefore neglecting drug diffusion and cell movement. Secondly, no biochemistry is included in the mathematical 
framework so that, for example, biochemical modulation and synergism between drugs are not incorporated. Finally, the KITT model does not describe 
host response to chemotherapy in terms of immunological reaction. 
Angiogenesis, or neovascularization, is the process of new blood vessels formation, typically promoted by the redundant activity of several growth factors, 
including vascular endothelial growth factor (VEGF), a potent inducer of endothelial cell proliferation and migration, preferentially expressed in hypoxic 
areas. The newly formed capillaries then undergo maturation, that involves pericyte coverage and stabilization. The major pericyte-stimulating factor is the 
platelet-derived growth factor (PDGF). Interactions between endothelial cells and pericytes are also governed by the angiopoietin system composed by two 
soluble factors, Angiopoietins 1 and 2 (Ang1 and Ang2, respectively). Ang1 promotes vessel maturation, while Ang2 acts as its natural antagonist. 
Angiogenesis occurs both in physiological events and in diseases. On the one hand, it allows survival of normal tissues when they become ischemic: on the 
other hand, pathological vascularization enables tumor growth and metastasis [67,68]. Beside their limitations, apparent advantages of approaches targeted 
to tumor angiogenesis include their universality for different solid tumors and the lack of prominent side effects and of resistance during repetitive 
treatment cycles. In this respect, the disclosed teachings in [36] provide a computer-implemented method for determining an optimal treatment protocol of 
a disease related to angiogenesis, including anti-angiogenic cancer therapies. Such a theoretical approach is based three interconnected modules, which 
respectively describe tissue growth, angiogenesis (immature vessels growth) and maturation (formation and stabilization of mature vessels). The tissue 
module simulates tissue cell proliferation and death, which are time- and nutrient-dependent, cell-type specific, and genetically determined. In particular, 
cell duplication and apoptosis rates are directly and inversely proportional, respectively, to the effective vascular density (EVD), which is a measure of the 
perfused part of the vascular tree. In the tissue module, VEGF and PDGF production are inversely related to EVD, so that increasing nutrient depletion 
results in an enhanced secretion of pro-angiogenic factors and consequent enhancement of vessel remodeling and maturation. The angiogenesis module 
deals with immature vessel volume, which is set to increase proportionally to VEGF concentration (if VEGF is above a given threshold level) and to decay 
if VEGF is below a possibly different threshold level (generally referred to as “survival level”). In the maturation module, it is assumed that maturation of 
immature vessels occurs if both pericytes concentration and Ang1/Ang2 ratio are above their respective threshold levels: in this considition, immature 
vessels do not undergo maturation, while mature vessels are destabilized and become immature. Volume of mature vessels is indeed coherently calculated 
according both to a given pericyte concentration and to the Ang1/Ang2 ratio. In particular, pericytes proliferate proportionally to PDGF concentration 
whereas Ang1 and Ang2 are secreted both by nutrient-depleted tissue cells and by immature vessels. Globally, the inputs needed by the computational 
method are the initial values of tissue volume and of blood vessels density in addition to selected chemical parameters. The outputs are the time evolution 
of mature and immature vessels sizes and the EVD. The efficacy of pro- or anti-angiogenic drugs (anti-VEGF signaling compounds) can be reproduced by 
setting their schedule (doses, number of concentrations, and treatment interval) and their effect on the proper mechanisms included in the model (inhibition 
of VEGF expression) as well as by analyzing the variation of the model outcomes compared to the no-treatment case.  
The prediction of drug response in individual patients can be improved by the integration of next generation sequencing (NGS) techniques, which allow 
large-scale analysis of tumor/patient genomes, epigenomes and transcriptomes. This issue has been addressed by a wide range of different strategies. An 
approach consists of a simple correlation of one or few biomarkers with published treatment outcomes or with mutational or transcriptomic profiles. 
Another one involves pattern matching or machine learning algorithms to find optimal drug treatment according to matching transcriptome or genome 
profiles. However, these procedures display unavoidable limitations, since combinations of biomarkers are either highly correlated (thereby allowing to 
subdivide a patient population in two or few groups) or not (thereby allowing the clusterization into too small groups, from a statistical viewpoint). More 
severely, such approaches do not take into account complex data on regulation and connectivity of cancer pathways. A patent by Kuhn and colleagues [38] 
suggests a computer model able to identify a therapeutic drug combination against a tumor, even if the disease includes alterations (mutations, 
overexpression, fusions, epigenetic changes and/or insertions) in at least two different but crosstalking signaling pathways. In particular, the inventors 
claim that treatment strategies targeting several signaling pathways in parallel might provide an improved treatment scheme compared with single-drug 
therapies. In fact, tumors often escape monotherapies due to additional mutations in another pathway, which may redirect the signaling cascade, thereby 
rendering the effect of an single drug almost ineffective. The present method consists of a kinetic model for the tumor of interest, which is based on a 
network topology approach. The nodes of the resulting graph represent biological entities, such genes, transcripts, nucleic acids, peptides, proteins, small 
molecules, complexes, or metabolites. The edges of the network describe the interactions between the biological entities. Interactions include conversion of 
one or more given biological entities into different ones, possibly under the influence of further biological elements, changes of biological entities amount, 
for example as a consequence of the action, presence or absence of other biological entities. Interactions between network variables are then modeled using 
mass action kinetics, which require the knowledge of kinetic laws and constants and of the (starting) concentrations of substrates or reactants. However, the 
exact values of specific parameters can not be often directly measured. This problem is overcome by a Monte Carlo-based approach, in which the unknown 
data are drawn from probability distributions, generating random parameter vectors eventually used to model patient states (different treatments or different 
treatment combinations). The tumor alterations or the effects of a drug therapy are modeled by proper variations in kinetic laws, constants and/or 
biomolecule concentrations, as known from the literature or by using inferences from bioinformatics technologies. For instance, missense mutations that 
damage known functional domains can be modeled by removing the appropriate edge between the modeled biological entity, whereas a drug that changes 
the efficiency of an enzymatic biological entity is modeled by multiplying the corresponding kinetic constant by a factor experimentally determined or 
selected from a lognormal distribution. Also in this case, an optimization procedure is finally employed to establish the more promising drug schedules. It 
is possible to simulate the effect of the combination of at least two chemotherapeutic compounds in the overall tumor network and to analyze how the 
multi-drug treatment affects the signaling pathway crosstalk as well. The derivation and the subsequent use of kinetic models of biological networks for 
clinical purposes is addressed also in patent [69]. Interestingly, the authors claim that, by the use of their approach, the construction of a “kinetic graph” of 
a biological system can be done even if only one part of the kinetic constants and/or of the starting concentrations are known or derived from experimental 
data. By employing a Monte Carlo method, the remaining fraction of parameters can indeed be chosen from appropriate probability distributions, including 
uniform, exponential, Poisson, Binomial, Cauchy, Beta, Gaussian, and lognormal laws. Indeed, the usual outcomes of the biological network, such as 
steady-state or equilibrium concentrations of selected biological entities, depend on the values assigned to the unknown, randomly chosen, parameters. The 
unknown data can be optimized by minimizing the difference between predicted and observed quantities. This process may involve continuous 
optimization and therefore non-linear regression-type approaches. Alternatively or in addition, optimization may involve discontinuous steps, such as 
modifications of the topology of the network and/or of kinetic laws. Therefore, the proposed patent can be used to evaluate unknown effects of drugs on 
selected biological entities. Further, this invention allows the simulation of interactions between networks, which may represent different cells, leading to a 
description of multi-cellular assemblies, tissues, organs, entire organisms or populations. 
Drug repositioning is the issue tackled by patent [70]. In particular, the invention allows to define drugs or drug combinations for treating unmet medical 
needs. The proposed method first involves the selection of the diseases to be treated, including cancer, neurodegenerative disorders, and neuropathies. 
Then, a dynamic model of the disease is built to define the most relevant mechanisms or cell targets by which the disease may be influenced or corrected 
by therapy. In particular, it is possible to focus on disease-associated pathways or groups of pathways rather than on isolated gene(s). The proposed 
technique allows to employ a global statistical analysis of all SNPs (single nucleotide polymorphisms) of each pathway accounted in the model of the 
disease. Other methods of gene product identification such as proteomic, metabolomic etc., are equally suitable for the identification of the disease-related 
pathways as well. An in silico screening of drugs affecting the pathways, identified as relevant for therapeutic interventions, can be then accomplished. 
This test can be performed from a library of approved drugs by making hypotheses on their use, known activities and/or putative synergic effects. Finally, 
the candidate compounds are tested in suitable in vitro and/or in vivo disease models, in order to evaluate their potential efficacy and toxicity. 
Some attempts to improve the efficiency of the drug discovery and development procedure also employ large-scale computing technology, in particular 
bioinformatics tools and infrastructures. The authors of the patent [39] report a method for a computer-assisted biomedical investigation that consists in 
mapping pharmaceutical knowledge into a three-dimensional domain, whose coordinate axes pertain disease, targets, and drug compounds, respectively. In 
order to achieve a complete and systematic analysis, the axes themselves are set up to be substantially comprehensive. For example, the disease axis may 
be derived from one or more dictionaries or encyclopedias of pathologies. The compound axis may be obtained from databases of drugs that are being 
marketed or that have been disclosed as under development. The target axis may be taken from the list of genes and protein products, expressed from one 
or more genomes, that are known to interact with the compounds on the drug axis. Some embodiments support additional possibilities for the axes, such as 
anatomy, tissue type, cell type, experimental procedure and so on. Note that the number of entities on an axis can be significantly lower than the number of 
entities on another axis. An information item is then placed within the three-dimensional space, according to the position on the coordinate axes of the 
entities it is linked with. Turning this around, the existence of the information item can be the evidence of a correlation between the corresponding entities. 
Entering in more details, an information item is linked to an entity by performing a textual search in selected literature databases of pharmaceutical, 
biological and medical research papers. An information item could also be linked to an entity by performing a textual search of one of its synonyms. This 
mapping is used to integrate various and diverse sources of textual, numerical, and graphical data as well as to specify a candidate hypothesis of the generic 
formula “A is related to B”, where A is selected from an axis and B from a second axis. Therefore, the proposed approach supports the systematic 
identification of potential indications and other medical utilities for drugs and drug targets, of new combinations of medicaments, of biomarkers and 
surrogate markers to aid drug discovery, clinical diagnostics and/or patient profiling to identified indication(s). The analysis can address questions of 
toxicity, adverse effects, or other drug safety data, and/or of drug-drug interactions for identifying adverse effects or undiscovered synergies for the 
development of therapeutic medicaments as well. A number of filters may be applied to the axes and/or to the search results, in order to improve their 
usefulness. For example, if the second axis represents targets, those entities for which no compound has been launched are excluded. This focuses 
investigations on targets related to available marketed drugs. The search results are generally presented as a list of the values ordered according to the 
number of information items that support the candidate hypothesis. Results may also be ranked (and/or filtered) using semantic algorithms, which typically 
generate and rank correlations between terms. Similarly, another patent [71] describes a procedure to create and use knowledge patterns, such as a self-
organizing knowledge map, for recognizing previously unseen or unknown correlations within the large amount of pharmaceutical data, obtained by virtual 
screening. A two-dimensional table that maps compounds against targets is finally proposed in [72], based on a comprehensive screening of experimental 
results: it can be used, for example, to predict a potential use of a new compound, say “A”, since it allows to link the targets to a drug, say “B”, that is 
associated to the compound of interest “A”. 
 
Finally, human cancer progression simulation is addressed by patent [73]. In particular, the authors claim that their Human Cancer Virtual Simulation (and 
related software) predicts tumor growth and metastasis starting from biological and medical research information. In particular, users enter individual 
patient data and then a series of mathematical algorithms screen selected databases (both genetic, molecular, and statistical) searching for results on the 
features of the tumor. In this way, information is provided about past, present and the future desease development. The invention has distinct modules, each 
of them dealing with different tumor aspects: (i) origin (original genetic mutations found to be the initiatory step of the disease); (ii) individual cell 
properties (cell-cycle timing, rate of mitosis or survival); (iii) colony properties (phenotypic relationships between malignant cells, such as collective 
nutrient consumption and adhesive forces); (iv-v) properties of the entire tumor and the host tissue (size and shape of the malignant mass and its 
interactions with the surrounding environment, such as with vascular and lymphatic systems); (vi) metastatic potential (ability to invade the host at distant 
sites, possible effects of surgery and pharmacological treatments). The underlying assumption (which is also its main drawback) is that cancer behavior is 
similar to that documented for analogous diseases. The human cancer virtual simulation engine can be continuously refined both by increasing the stored 
data from the medical/biological research and by improving the mathematical search algorithms.  
The occurrence and the clinical outcomes of specific gene expression and mutations in cancer and related diseases is tackled by some of the previously 
presented patents. Further, it is the focus of other inventions that, strictly speaking, are based on statistical methods, such as Bayesian networks, hidden 
Markov models and other machine learning techniques, with relative bioinformatics tools. For instance, patent [74] allows to differentiate clinical 
conditions associated with breast cancer by the use of a computer software for data analysis of microarrays. In particular, the disclosed technique is able to 
distinguish between  BRCA1 and sporadic tumors and to provide information on estrogen receptor ESR1 expression and on the likelihood of malignant 
distant metastases within five years of initial diagnosis. Invention [75] provides methods for detecting the presence of gene mutations associated to early 
colorectal cancer. Statistical approaches, including sequential probability ratio testing (SPRT), are also used to provide relevant genetic information on an 
individual (mainly related to cancer-associated diseases) [76], to evaluate the possibility that progeny of two subjects will exhibit one or more phenotypic 
attributes, and to determine (by defining a proper cutoff value) whether a nucleic acid sequence imbalance exists within a biological sample [77]. A 
penalized discriminant analysis, an extension of the Fisher's linear discriminant analysis, is then proposed in [78] for the study of gene expression profile 
microarrays, in order to define the presence or the stage of a selected disease, disorder, or genetic pathology in a mammalian subject. Such a technique 
includes the examination of a sample containing patients immune cells and the evaluation of the expression variability in a statistically significant number 
of genes compared either with average healthy or altered gene expression profiles. Further, in [79], the authors propose a method to determine whether an 
individual is at risk for developing prostate cancer at a later date or whether he suffers from prostate cancer as a result of PG1 gene mutation. This 
approach involves a statistical analysis based on the LOD score of chromosomal regions potentially harboring a candidate gene associated with a sporadic 
trait. Finally, a series of patents by Schadt and coworkers reports statistical methods, mainly multivariate analysis, and relative computer systems to 
associate a query QTL or a query gene with traits using cross species data [80] and to identify genes and/or pathways associated with a trait [81]. 
CURRENT & FUTURE DEVELOPMENTS 
Theoretical methods can be viewed as a useful tool for translational medicine to identify novel therapeutic targets, to provide insight in the mechanisms 
underlying drug resistance and to predict alternative therapeutic strategies. From a computational point of view, anti-cancer drug development is an 
optimization problem which involves the maximization of cancer cell death and concomitantly the minimization of toxicity levels. However, despite the 
aforementioned promising beginnings, there is a low number of patents involving mathematical approaches in drug discovery. A possible explanation is 
that the outcomes of purely modelling approaches are not yet sufficiently accurate and/or reproducible in experimental trials. Further, the 
oversimplification of complex biological events, which is often necessary due to computational limitations, gives rise to implausible or unfeasible 
evidence. Finally, theoretical methods are usually based on a wide range of parameters and coefficients lacking direct biological correspondence, being 
therefore difficult to be properly and realistically estimated. For these reasons, mathematical-based approaches still need more time and effort to be more 
convincing and to become an integral component of the pharmaceutical practice. A significant improvement will be achieved through a closer 
collaboration between researchers from different backgrounds, leading to multidisciplinary work teams.  
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Figure legend 
Figure 1: The systems biology workflow. In silico and in vitro approaches are integrated and interfaced in a continuous feedback and feedforward of 
information. In particular, initial experimental observations, translated in mathematical language, constitute the hypothesis of a first simple 
model. After multiple cycles of experimental validation, the computational method can be finally used in a predictive way to improve biomedical 
knowledge.     
